Skip to main content
OpenTrials
Completed

NCT Number: NCT00819117

Investigation of Transvenous Versus Epicardial Left Ventricular Stimulation Technique

The purpose of this study is to demonstrate that epicardial and transvenous left ventricular leads are safe and effective for cardiac resynchronization therapy in heart failure patients implanted with a CRT device.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ospedale Cisanello, Pisa, Italy

Loading trial locations.

About this study

This clinical trial is a multicenter, prospective, randomized, parallel, open study designed to compare epicardial left ventricular pacing to transvenous left ventricular pacing for delivering cardiac resynchronization therapy.

After a pre-implant baseline evaluation, patients will be randomized in a 1:1 fashion to one of two groups:

  • Control group: resynchronization via a transvenous left ventricular lead (TVN CRT);
  • Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT).

All patients taking part in this study will undergo the implantation of a CRT device with or without ICD back-up (depending on the physician's decision), with right atrial and right ventricular transvenous leads.

Patients will attend protocol scheduled visits before implant (pre-implant baseline evaluation), and post-implant: before hospital discharge, 6 weeks post-implant (optional visit), 3 months (optional visit), and 6 months after implant, time of study termination.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have an approved indication for implantation of an CRT device (ESC guidelines , including any update);
  • Have a stable pharmacological therapy.

Exclusion criteria

  • Have a contra-indication to general anesthesia;
  • Have a scheduled cardiac surgery;
  • Have had a recent myocardial infarction, unstable angina or cardiac revascularization (PTCA or CABG) within 1 month of enrollment;
  • Have a life expectancy of less than 6 months;
  • Are unable to provide informed consent;
  • Are unable to comply with the follow-up schedule and tests;
  • Are minor (age below 18 years);
  • Are pregnant or are planning for pregnancy in the next 6 months.

Treatment and study plan

Cardiac Resynchronization Therapy implant

Device

Device implant with appropriate leads

Primary outcomes

  1. The efficacy will be evaluated by comparing the pacing thresholds at 6 months between the two groups. The safety will be evaluated by comparing the survival from lead-related complications at 6 months between the two groups.

    Time frame: 6 months follow up after implant

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Acronym: INTREPID

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jan 8, 2009
Registry last updated
Feb 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.